Therapeutic Effects of PEG-Modified Polyamide Amine Dendrimer for Cell Free DNA Adsorption in Temporomandibular Joint Osteoarthritis
ACS Applied Materials & Interfaces · 31.07.2024 · 16 (30) · 39153-39164
DOI: 10.1021/acsami.4c08569 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 17.07.2024. Verfasst von Yuzhuo Hei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Temporomandibular Joint, Affiliated Stomatology Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 51014…. Hauptthemen laut MEDLINE: Dendrimers, Osteoarthritis, Polyethylene Glycols, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Guangdong Provincial Department of Science and Technology, Guangzhou Municipal Science and Technology Bureau, Guangzhou Municipal Science and Technology Project.
Abstract (Originalsprache)
Temporomandibular joint osteoarthritis (TMJ OA) is characterized by the degeneration of cartilage and subchondral bone. In this study, we observed a significant increase in cell-free DNA (cfDNA) levels during the progression of TMJ OA. Bioinformatics analysis identified TLR9 as a pivotal molecule in TMJ OA pathogenesis. The polyamidoamine (PAMAM) dendrimer characterized by a well-structured, highly branched, and reactive nature, exhibits robust binding and clearance capabilities for cfDNA. However, the abundant amino groups on the surface of PAMAM lead to its inherent toxicity. To mitigate this, PEG-5000 was conjugated to the surface of PAMAM dendrimers, enhancing safety. Our results indicate that PEG-PAMAM effectively inhibits the upregulation of the TLR9 protein in TMJ OA, significantly suppressing the activation of the p-IκBα/p-NF-κB signaling pathway and subsequently decreasing chondrocyte inflammation and apoptosis, as evidenced by both in vivo and in vitro experiments. We conclude that PEG-PAMAM is a safe and effective material for in vivo applications, offering a promising therapeutic strategy for TMJ OA by targeting cfDNA clearance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Temporomandibular Joint, Affiliated Stomatology Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510140, China.
- Guangdong Engineering Research Center of Oral Restoration and Reconstruction, Guangzhou Key Laboratory of Basic and Applied Research of Oral Regenerative Medicine, Guangzhou 510182, China.
- Department of Anesthesiology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, People's Republic of China.
ORCID-Profile: Yifan Deng, Qingbin Zhang
Förderung
- Guangdong Provincial Department of Science and Technology
- Guangzhou Municipal Science and Technology Bureau
- Guangzhou Municipal Science and Technology Project
- National Natural Science Foundation of China
Zitieren
APA
Hei, Y., Du, J., Deng, Z., Deng, Y., Guan, Y., Yang, J., Chen, S., Zhang, Z., Jiang, S., & Zhang, Q. (2024). Therapeutic Effects of PEG-Modified Polyamide Amine Dendrimer for Cell Free DNA Adsorption in Temporomandibular Joint Osteoarthritis. ACS Applied Materials & Interfaces, 16(30), 39153-39164. https://doi.org/10.1021/acsami.4c08569
Vancouver
Hei Y, Du J, Deng Z, Deng Y, Guan Y, Yang J, et al. Therapeutic Effects of PEG-Modified Polyamide Amine Dendrimer for Cell Free DNA Adsorption in Temporomandibular Joint Osteoarthritis. ACS Applied Materials & Interfaces. 2024;16(30):39153-39164. doi:10.1021/acsami.4c08569
BibTeX
@article{Hei2024,
author = {Hei, Yuzhuo and Du, Jingyi and Deng, Zhizhao and Deng, Yifan and Guan, Yu and Yang, Jing and Chen, Sufang and Zhang, Ziyi and Jiang, Siqing and Zhang, Qingbin},
title = {Therapeutic Effects of PEG-Modified Polyamide Amine Dendrimer for Cell Free DNA Adsorption in Temporomandibular Joint Osteoarthritis},
journal = {ACS Applied Materials & Interfaces},
year = {2024},
volume = {16},
number = {30},
pages = {39153--39164},
doi = {10.1021/acsami.4c08569}
}
EUVIMED